Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,030.00 Price Target at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by TD Cowen from $1,020.00 to $1,030.00 in a research note released on Wednesday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. Royal Bank of Canada reissued an outperform rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Bank of America boosted their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an underperform rating in a research report on Friday, April 12th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a research report on Tuesday, January 23rd. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an outperform rating and a $1,125.00 target price on the stock. Finally, Cantor Fitzgerald restated a neutral rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of Moderate Buy and a consensus target price of $977.77.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $906.54 on Wednesday. The firm’s 50 day moving average price is $950.58 and its two-hundred day moving average price is $893.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The firm has a market cap of $99.50 billion, a P/E ratio of 26.09, a PEG ratio of 2.61 and a beta of 0.11. Regeneron Pharmaceuticals has a twelve month low of $684.80 and a twelve month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $10.96 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals will post 38.8 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. IFP Advisors Inc lifted its position in Regeneron Pharmaceuticals by 9.7% during the third quarter. IFP Advisors Inc now owns 442 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 39 shares during the period. Global Retirement Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 67.1% in the third quarter. Global Retirement Partners LLC now owns 249 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 100 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% in the third quarter. Park Place Capital Corp now owns 95 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 15 shares during the last quarter. Private Trust Co. NA lifted its holdings in shares of Regeneron Pharmaceuticals by 30.4% in the third quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 94 shares during the last quarter. Finally, CX Institutional lifted its holdings in shares of Regeneron Pharmaceuticals by 10.7% in the third quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.